Objective :To evaluate the efficacy and toxicity of combined therapy with oxaliplatin and capecitabine ( XELOX ) in patients with metastatic gastric cancer. Methods : Total of 54 patients with previously untreated metastatic gastric cancer received intravenous infusion of oxaliplatin at the dose of 130 mg/m2 on day 1 and oral administration of capecitabine at the dose of 1000 mg/m2 twice per day on day 1 - 14. The chemotherapy was repeated every 3 weeks. Results : Four of 54 patients achieved complete response,24 partial responses, with an overall response rate of 51. 8％ . Stable disease was observed in 18 patients and progressive disease in 8. The median time to progression and overall survival was 6. 2 months and 11. 8 months with 35. 1％ of 1 - year survival rate. All 54 patients were evaluated for toxic effects according to WHO toxicity criteria,4 patients showed grade Ⅲ - Ⅳ neural toxicity , hematological toxicity, digestive system toxicity, and 3 had hand - foot syndrome at the grade of Ⅲ - Ⅳ . Conclusion : XELOX regimen shows great efficacy with an acceptable toxicity profile in metastatic gastric cancer.%目的:观察奥沙利铂联合卡培他滨(XELOX)方案一线治疗转移性胃癌的疗效及安全性.方法:2004年1月-2007年6月西安交通大学医学院第一附属医院肿瘤外科收治的、经组织学证实的转移性胃腺癌患者54例,接受XELOX方案化疗,奥沙利铂 130 mg/m2,静脉滴注4h,第1天;卡培他滨 1000 mg/m2,口服 2次/天,第1-14天,每3周重复一次,每2周期后进行疗效评估.结果:54例接受XELOX方案一线治疗的患者均可评价疗效,CR 4例,PR 24例,SD 18例,PD 8例,总有效率为51.8%,临床获益率为85.1%,中位肿瘤进展时间6.0月,中位生存时间12.1月,1年生存率35.1%;XELOX方案治疗发生Ⅲ-Ⅳ级不良反应,其中神经毒性、血液学毒性和消化系统毒性各4例,手足综合征5例.结论:XELOX方案作为一线治疗晚期转移性胃癌疗效肯定,安全性高,不良反应轻,患者耐受性好.
展开▼
